Omeros gets faster FDA review of Huntington’s drug

NEW YORK (AP) — Drug developer Omeros said Wednesday that regulators will conduct a faster review of its drug OMS824, a treatment for cognitive impairment in patients with Huntington’s disease…. …read more

From: AP Washington News